Companies / Femasys Inc

Femasys Inc

Nasdaq: FEMYCIK 1339005SUWANEE, GA

Financials · FY2025

Revenue$2.29M
Net income$-18.63M
Total debt—
Cash$5.39M
Diluted EPS$-0.47
Shares outstanding60.4M

Ownership

60.4M shares outstanding · as of May 7, 2026
16.0%Institutions
Ownership
Institutions15.99%9,657,018
Public float84.01%50,733,668

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 8

View all →
Insider% of sharesShares
Canning John CharlesFormerChief Operating Officer
——
Eichenbaum Kenneth D.Director
——
Elefant DovChief Financial Officer
——
Larsen CharlesDirector
——
Lee-Sepsick KathyCEOChief Executive Officer · Director
——
PharmaCyte Biotech, Inc.10% owner
——
Silverman JoshuaFormerDirector
——
Sipos Jeremy AlexanderFormerChief Technology Officer
——

Institutional holders 39

View all →
HolderValue% of shares
Dauntless Investment Group, LLC$849.5K9.82%
Vanguard Group Inc$815.4K2.34%
Barclays PLC$295.0K0.16%
Geode Capital Management, LLC$261.1K1.03%
Citadel Advisors LLC$197.2K0.57%
BTGP Boreas Fund LP - Series A$87.7K0.25%
Clear Creek Financial Management, LLC$63.2K0.18%
Jane Street Group, LLC$61.7K0.18%
UBS Group AG$52.4K0.15%
State Street Corporation$46.6K0.13%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 30, 2026Canning John Charles
Executive
GrantStock Option (Right to Buy)—+150K
150,000
0.25% of shares
low
Mar 19, 2026Eichenbaum Kenneth D.
Director
GrantSeries D-1 Warrants—+102K
102,366
0.17% of shares
low
Mar 19, 2026Larsen Charles
Director
GrantSeries D-1 Warrants—+34K
34,122
0.06% of shares
low
Mar 19, 2026Lee-Sepsick Kathy
CEO
GrantSeries D-1 Warrants—+68K
68,244
0.11% of shares
low
Mar 19, 2026Elefant Dov
Executive
GrantSeries D-1 Warrants—+34K
34,122
0.06% of shares
low
Mar 18, 2026Eichenbaum Kenneth D.
Director
GrantStock Option (Right to Buy)—+35K
35,200
0.06% of shares
low
Feb 19, 2026Lee-Sepsick Kathy
CEO
GrantRestricted Stock Units—+282K
282,000
0.47% of shares
low
Feb 19, 2026Lee-Sepsick Kathy
CEO
GrantRestricted Stock Units—+447K
447,000
0.74% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
PharmaCyte Biotech, Inc.Passive13G———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
FEMYCommon StockEquity31447E204BBG004M23R63
FEMY——31447E105—